Stock BCTX BRIACELL THERAPEUTICS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

All News BriaCell Therapeutics Corp. Nasdaq

Equities

BCTX

CA1079301091

Market Closed - Nasdaq
Other stock markets
 20:58:31 16/07/2024 BST 		5-day change 1st Jan Change
0.978 USD +5.16% Intraday chart for BriaCell Therapeutics Corp. -5.05% -83.28%
06-14 BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024 CI
06-03 Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Form 8 K
PU
BriaCell Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024
CI
BriaCell Presents Clinical Efficacy Data at ASCO 2024
AQ
Briacell Therapeutics Corp. Presents Clinical Efficacy Data At ASCO 2024
CI
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer
AQ
BriaCell Begins Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer
MT
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer
AQ
BriaCell Therapeutics Corp. Initiates Patient Enrollment in First-In-Human Study of Bria-Ots in Advanced Metastatic Breast Cancer
CI
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study
MT
BriaCell Therapeutics, BeiGene Partner to Test Combination of Companies' Cancer Treatments
MT
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
AQ
BriaCell Therapeutics Corp. Announces Clinical Supply Agreement with BeiGene, Ltd. for Bria-OTS First in Human Study
CI
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
AQ
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing
MT
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
AQ
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble
MT
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
AQ
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting
MT
BriaCell Announces Oral and Poster Presentations at ASCO 2024
AQ
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BCT Stock
  4. BCTX Stock
  5. News BriaCell Therapeutics Corp.